Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
MS in tijden van COVID-19
mei 2021 | Multipele Sclerose, Vaccinatie, Virale infecties